-
Nov 06, 2020 03:20 PM IST Consolidated revenue for the said quarter came at Rs 431.9 crore, up 18 percent YoY from Rs 365.6 crore in the corresponding quarter of the previous financial year.
-
Oct 14, 2020 10:22 AM IST Diagnostic firms such as Dr Lal PathLabs, Thyrocare Technologies and Metropolis Healthcare rebound as COVID-19 related tests drive business growth. While non COVID-19 business is showing signs of normalisation, sustainability of recovery is key
-
Oct 09, 2020 08:44 PM IST The data included patients’ booking details such as their name, address, phone number, email id, payment details, digital signature, and also the type of medical tests they had taken.
-
Aug 09, 2020 09:02 AM IST Geojit recommended recommended hold rating on Dr. Lal PathLabs with a target price of Rs 1995 in its research report dated August 06, 2020.
-
Aug 08, 2020 12:34 PM IST Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 1006 in its research report dated August 03, 2020.
-
Jul 31, 2020 03:06 PM IST Its revenue was down 20.6% at Rs 266 crore against Rs 335.2 crore.
-
Jul 15, 2020 02:02 PM IST Despite the turmoil caused by COVID-19, the stock has been gaining significantly in the calendar year 2020 so far. The stock has gained 27 percent as of July 14 close on BSE against a 13 percent fall in benchmark Sensex.
-
Jul 07, 2020 04:25 PM IST The company, in its Annual Report for 2019-20, stated that instances and situations like the COVID-19 outbreak further boost the importance of diagnostics as an integral part of healthcare system.
-
May 19, 2020 11:05 AM IST Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 895 in its research report dated May 19, 2020.
-
Mar 18, 2020 11:24 AM IST The total number of coronavirus cases in India rose to 147, with 10 fresh cases reported from various parts of the country.
-
Feb 04, 2020 11:32 AM IST The company reported a 19.08 percent year-on-year increase in consolidated net profit at Rs 54.9 crore for the quarter ended December 31.
-
Feb 03, 2020 04:25 PM IST The company had posted a net profit of Rs 46.1 crore in the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to the BSE.
-
Feb 03, 2020 03:35 PM IST -
Oct 11, 2019 03:26 PM IST Net Sales are expected to increase by 14.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 364.5 crore, according to Kotak.
-
Sep 04, 2019 11:09 AM IST The overall demand for Gold and silver investments have also increased in the current period to an all-time high, due to volatile Indian equity markets and further concerns about the health of the Indian economy.
-
Aug 14, 2019 04:30 PM IST Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1120 in its research report dated August 14, 2019.
-
Jul 15, 2019 02:59 PM IST Net Sales are expected to increase by 14 percent Y-o-Y (up 10.7 percent Q-o-Q) to Rs. 333.2 crore, according to Kotak.
-
Jul 12, 2019 04:45 PM IST Net Sales are expected to increase by 15 percent Y-o-Y (up 11.6 percent Q-o-Q) to Rs. 336.1 crore, according to Prabhudas Lilladher.
-
May 17, 2019 04:00 PM IST -
Apr 17, 2019 03:06 PM IST Net Sales are expected to increase by 15.3 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 307.7 crore, according to Kotak.
-
Apr 12, 2019 12:56 PM IST Net Sales are expected to increase by 30.2 percent Y-o-Y (up 18.8 percent Q-o-Q) to Rs. 347.4 crore, according to Prabhudas Lilladher.
-
Apr 11, 2019 08:05 PM IST The 75 companies can return a median of 49 percent of their total cash and cash equivalents to their shareholders.
-
Apr 02, 2019 11:01 AM IST At 1015 hrs, Dr Lal PathLabs was quoting Rs 1076, up 2.81 percent on the BSE.
-
Feb 18, 2019 02:11 PM IST Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1070 in its research report dated February 11, 2019.
-
Feb 11, 2019 10:48 AM IST